Trabectedin First Line Therapy In Unfit Sarcoma Study (TR1US)
SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
Sponsor: Italian Sarcoma Group
Listed as NCT02066675, this PHASE2 trial focuses on Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive and Standard Chemotherapy and remains completed. Sponsored by Italian Sarcoma Group, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Italian Sarcoma Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Bergamo, Italy , Bologna, Italy , Candiolo, Italy , Frosinone, Italy , Genova, Italy , Meldola, Italy , Napoli, Italy , Padua, Italy , Palermo, Italy and 3 more locations